89 related articles for article (PubMed ID: 14628576)
1. [Cefepime/amikacin in the empirical antibacterial therapy for patients with hemoblastosis of different forms].
Chudanova TV; Abdulkadyrov KM; Chebotkevich VN
Antibiot Khimioter; 2003; 48(7):29-32. PubMed ID: 14628576
[TBL] [Abstract][Full Text] [Related]
2. Cefepime monotherapy is as effective as ceftriaxone plus amikacin in pediatric patients with cancer and high-risk febrile neutropenia in a randomized comparison.
Pereira CA; Petrilli AS; Carlesse FA; Luisi FA; da Silva KV; de Martino Lee ML
J Microbiol Immunol Infect; 2009 Apr; 42(2):141-7. PubMed ID: 19597646
[TBL] [Abstract][Full Text] [Related]
3. [Cefepime-amikacin combination in febrile neutropenic children with malignant hemopathy or tumor].
Marie-Cardine A; Schneider P; Blot N; Tron P; Vannier JP
Arch Pediatr; 2003 Apr; 10(4):307-12. PubMed ID: 12818750
[TBL] [Abstract][Full Text] [Related]
4. Cefepime/amikacin versus ceftazidime/amikacin as empirical therapy for febrile episodes in neutropenic patients: a comparative study. The French Cefepime Study Group.
Cordonnier C; Herbrecht R; Pico JL; Gardembas M; Delmer A; Delain M; Moreau P; Ladeb S; Nalet V; Rollin C; Gres JJ
Clin Infect Dis; 1997 Jan; 24(1):41-51. PubMed ID: 8994754
[TBL] [Abstract][Full Text] [Related]
5. Cefepime monotherapy as an empirical initial treatment of patients with febrile neutropenia.
Montalar J; Segura A; Bosch C; Galan A; Juan O; Molins C; Giner V; Aparicio J
Med Oncol; 2002; 19(3):161-6. PubMed ID: 12482126
[TBL] [Abstract][Full Text] [Related]
6. Comparison of cefepime versus ceftriaxone-amikacin as empirical regimens for the treatment of febrile neutropenia in acute leukemia patients.
Borbolla JR; López-Hernández MA; González-Avante M; DeDiego J; Trueba E; Alvarado ML; Jiménez RM
Chemotherapy; 2001; 47(5):381-4. PubMed ID: 11561142
[TBL] [Abstract][Full Text] [Related]
7. Comparison of cefepime and ceftazidime in combination with amikacin in the empirical treatment of high-risk patients with febrile neutropenia: a prospective, randomized, multicenter study.
Erman M; Akova M; Akan H; Korten V; Ferhanoğlu B; Köksal I; Cetinkaya Y; Uzun O; Unal S;
Scand J Infect Dis; 2001; 33(11):827-31. PubMed ID: 11760163
[TBL] [Abstract][Full Text] [Related]
8. Cefepime plus amikacin as an initial empirical therapy of febrile neutropenia in paediatric cancer patients.
Hamidah A; Lim YS; Zulkifli SZ; Zarina AL; Nordiah AJ; Jamal R
Singapore Med J; 2007 Jul; 48(7):615-9. PubMed ID: 17609821
[TBL] [Abstract][Full Text] [Related]
9. A randomized clinical trial of ceftriaxone and amikacin versus piperacillin tazobactam and amikacin in febrile patients with hematological neoplasia and severe neutropenia.
Rossini F; Terruzzi E; Verga L; Larocca A; Marinoni S; Miccolis I; Giltri G; Isella M; Parma M; Pogliani EM
Support Care Cancer; 2005 Jun; 13(6):387-92. PubMed ID: 15599778
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of cefepime and amikacin in the empiric treatment of febrile neutropenic children with cancer.
Chastagner P; Plouvier E; Eyer D; Plesiat P; Lozniewski A; Sommelet D
Med Pediatr Oncol; 2000 Apr; 34(4):306-8. PubMed ID: 10742081
[No Abstract] [Full Text] [Related]
11. Randomized trial of cefepime monotherapy or cefepime in combination with amikacin as empirical therapy for febrile neutropenia.
Tamura K; Imajo K; Akiyama N; Suzuki K; Urabe A; Ohyashiki K; Tanimoto M; Masaoka T;
Clin Infect Dis; 2004 Jul; 39 Suppl 1():S15-24. PubMed ID: 15250016
[TBL] [Abstract][Full Text] [Related]
12. [Clinical evaluation of combination therapy with cefpirome and amikacin for infections associated with hematological disorders].
Fukuda M; Kobayashi Y; Endo K; Kawai N; Tominaga K; Bessho M; Hirashima K
Jpn J Antibiot; 1998 Apr; 51(4):298-304. PubMed ID: 9644603
[TBL] [Abstract][Full Text] [Related]
13. A prospective study of cefepime versus ticarcilline/clavulanate as empirical treatment of febrile neutropenia in lymphoma patients.
Naseem A; Hussain Y; Ahmad B; Aziz MT; Ahmad M; Hameed H
J Pak Med Assoc; 2011 Jan; 61(1):18-22. PubMed ID: 22368896
[TBL] [Abstract][Full Text] [Related]
14. Cefepime as empirical monotherapy in febrile patients with hematological malignancies and neutropenia: a randomized, single-center phase II trial.
Engervall P; Kalin M; Dornbusch K; Björkholm M
J Chemother; 1999 Aug; 11(4):278-86. PubMed ID: 10465130
[TBL] [Abstract][Full Text] [Related]
15. Randomized controlled trial comparing oral amoxicillin-clavulanate and ofloxacin with intravenous ceftriaxone and amikacin as outpatient therapy in pediatric low-risk febrile neutropenia.
Gupta A; Swaroop C; Agarwala S; Pandey RM; Bakhshi S
J Pediatr Hematol Oncol; 2009 Sep; 31(9):635-41. PubMed ID: 19684522
[TBL] [Abstract][Full Text] [Related]
16. [Clinical effects of combination therapy with cefozopran and amikacin for infections in patients with hematological disorders].
Fukuda M; Endo K; Takinami S; Kawai N; Tominaga K; Maesaki S; Bessho M; Yamazaki T
Jpn J Antibiot; 2001 Feb; 54(2):88-94. PubMed ID: 11338682
[TBL] [Abstract][Full Text] [Related]
17. Cefepime and amikacin as empirical therapy in patients with febrile neutropaenia: a single-centre phase II prospective survey.
Mebis J; Vandeplassche S; Goossens H; Berneman ZN
Acta Clin Belg; 2009; 64(1):35-41. PubMed ID: 19317239
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness of ceftriaxone and amikacin as single daily dose for the empirical management of febrile granulocytopenic children with cancer.
Pession A; Prete A; Paolucci G
Chemotherapy; 1997; 43(5):358-66. PubMed ID: 9309370
[TBL] [Abstract][Full Text] [Related]
19. Cefepime Versus Cefepime Plus Amikacin as an Initial Antibiotic Choice for Pediatric Cancer Patients With Febrile Neutropenia in an Era of Increasing Cefepime Resistance.
Lee NH; Kang JM; Lee JW; Huh HJ; Lee NY; Yoo KH; Sung KW; Koo HH; Kim YJ
Pediatr Infect Dis J; 2020 Oct; 39(10):931-936. PubMed ID: 32453199
[TBL] [Abstract][Full Text] [Related]
20. Ceftriaxone versus ceftazidime plus aminoglycoside therapy for infections in patients with neutropenia after cytotoxic chemotherapy. Short communication.
Krcméry V; Danisovicová A; Drgona L; Spánik S; Fuchsberger P; Korec S; Svec J
Neoplasma; 1993; 40(2):103-5. PubMed ID: 8350953
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
